Literature DB >> 33616931

The multi-faceted role of mitochondria in the pathology of Parkinson's disease.

Dennison Trinh1, Ahmad R Israwi1, Lindsay R Arathoon1, Jacqueline A Gleave1, Joanne E Nash1.   

Abstract

Mitochondria are essential for neuronal function. They produce ATP to meet energy demands, regulate homeostasis of ion levels such as calcium and regulate reactive oxygen species that cause oxidative cellular stress. Mitochondria have also been shown to regulate protein synthesis within themselves, as well as within the nucleus, and also influence synaptic plasticity. These roles are especially important for neurons, which have higher energy demands and greater susceptibility to stress. Dysfunction of mitochondria has been associated with several neurodegenerative diseases, including Parkinson's disease, Alzheimer's disease, Huntington's disease, Glaucoma and Amyotrophic Lateral Sclerosis. The focus of this review is on how and why mitochondrial function is linked to the pathology of Parkinson's disease (PD). Many of the PD-linked genetic mutations which have been identified result in dysfunctional mitochondria, through a wide-spread number of mechanisms. In this review, we describe how susceptible neurons are predisposed to be vulnerable to the toxic events that occur during the neurodegenerative process of PD, and how mitochondria are central to these pathways. We also discuss ways in which proteins linked with familial PD control mitochondrial function, both physiologically and pathologically, along with their implications in genome-wide association studies and risk assessment. Finally, we review potential strategies for disease modification through mitochondrial enhancement. Ultimately, agents capable of both improving and/or restoring mitochondrial function, either alone, or in conjunction with other disease-modifying agents may halt or slow the progression of neurodegeneration in Parkinson's disease.
© 2020 International Society for Neurochemistry.

Entities:  

Keywords:  Parkinson's disease; animal models; cell and molecular mechanisms; genetic / familial Parkinson's disease; human studies; mitochondria; mitochondria enhancers and small molecules

Mesh:

Year:  2020        PMID: 33616931     DOI: 10.1111/jnc.15154

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  13 in total

Review 1.  Neurogenetic disorders across the lifespan: from aberrant development to degeneration.

Authors:  Richard A Hickman; Sarah A O'Shea; Mark F Mehler; Wendy K Chung
Journal:  Nat Rev Neurol       Date:  2022-01-05       Impact factor: 42.937

Review 2.  Targeting Mitochondria as a Therapeutic Approach for Parkinson's Disease.

Authors:  Maryam Abrishamdar; Maryam Sadat Jalali; Yaghoob Farbood
Journal:  Cell Mol Neurobiol       Date:  2022-08-11       Impact factor: 4.231

3.  Expanding Views of Mitochondria in Parkinson's Disease: Focusing on PINK1 and GBA1 Mutations.

Authors:  Yu Yuan; Xizhen Ma; Ning Song; Junxia Xie
Journal:  Neurosci Bull       Date:  2022-05-11       Impact factor: 5.271

4.  Mouse midbrain dopaminergic neurons survive loss of the PD-associated mitochondrial protein CHCHD2.

Authors:  Mai K Nguyen; Kevin McAvoy; Szu-Chi Liao; Zak Doric; Iris Lo; Huihui Li; Giovanni Manfredi; Ken Nakamura
Journal:  Hum Mol Genet       Date:  2022-05-04       Impact factor: 5.121

Review 5.  Disease-modifying treatment of Parkinson's disease by phytochemicals: targeting multiple pathogenic factors.

Authors:  Makoto Naoi; Wakako Maruyama; Masayo Shamoto-Nagai
Journal:  J Neural Transm (Vienna)       Date:  2021-10-15       Impact factor: 3.850

6.  Functional Impairment of the Nervous System with Glycolipid Deficiencies.

Authors:  Yutaka Itokazu; Takahiro Fuchigami; Robert K Yu
Journal:  Adv Neurobiol       Date:  2023

7.  Novel Macrocyclic LRRK2 Inhibitors for Treating Parkinson's Disease.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2022-01-03       Impact factor: 4.345

8.  Novel N-Heteroaryl Quinazolin-2-amine Derivatives as LRRK2 Inhibitors for Treating Parkinson's Disease.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2021-06-09       Impact factor: 4.632

Review 9.  The Causal Role of Lipoxidative Damage in Mitochondrial Bioenergetic Dysfunction Linked to Alzheimer's Disease Pathology.

Authors:  Mariona Jové; Natàlia Mota-Martorell; Pascual Torres; Victoria Ayala; Manuel Portero-Otin; Isidro Ferrer; Reinald Pamplona
Journal:  Life (Basel)       Date:  2021-04-25

Review 10.  The Influence of Mitochondrial Dynamics and Function on Retinal Ganglion Cell Susceptibility in Optic Nerve Disease.

Authors:  Nicole A Muench; Sonia Patel; Margaret E Maes; Ryan J Donahue; Akihiro Ikeda; Robert W Nickells
Journal:  Cells       Date:  2021-06-25       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.